









Markets
/
Stocks
/
nasdaq-vrtx
/

Vertex Pharmaceuticals Inc

VRTX

419.890USD

+2.680+0.64%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

107.61BMarket Cap

29.58P/E TTM



Vertex Pharmaceuticals Inc

419.890

+2.680+0.64%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vertex Pharmaceuticals Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vertex Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

37 / 160

Overall Ranking

99 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 33 analysts

Buy

Current Rating

482.212

Target Price

+14.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Vertex Pharmaceuticals Inc Highlights

StrengthsRisks

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 23.40% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 29.54, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 252.22M shares, decreasing 0.12% quarter-over-quarter.

Held by Jerome Dodson | PARNX

Star Investor Jerome Dodson | PARNX holds 1.65M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.81.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 9.11, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 2.96B, representing a year-over-year increase of 12.06%, while its net profit experienced a year-over-year increase of 128.74%.

Score

Industry at a Glance

Previous score

9.11

Change



Financials

9.21

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.85

Key Metrics

Free cash flow

No Data

Vertex Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 6.13, which is lower than the Pharmaceuticals industry's average of 7.22. Its current P/E ratio is 29.54, which is 14.94% below the recent high of 33.95 and 1044.06% above the recent low of -278.85.

Score

Industry at a Glance

Previous score

6.13

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 37/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 7.52, which is lower than the Pharmaceuticals industry's average of 7.79. The average price target for Vertex Pharmaceuticals Inc is 481.50, with a high of 603.00 and a low of 330.00.

Score

Industry at a Glance

Previous score

7.52

Change

Support & Resistance

No Data

Analyst Rating

Based on 33 analysts

Buy

Current Rating

482.212

Target Price

+15.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Vertex Pharmaceuticals Inc

VRTX

Biogen Inc

BIIB

Amgen Inc

AMGN

AbbVie Inc

ABBV

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 7.24, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 433.07 and the support level at 401.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.14

Change

-1.9

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.258

Neutral

RSI(14)

57.445

Neutral

STOCH(KDJ)(9,3,3)

40.009

Sell

ATR(14)

7.936

High Vlolatility

CCI(14)

20.685

Neutral

Williams %R

42.644

Buy

TRIX(12,20)

0.271

Sell

StochRSI(14)

38.976

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

420.210

Sell

MA10

421.230

Sell

MA20

415.434

Buy

MA50

401.228

Buy

MA100

421.399

Sell

MA200

445.649

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.79. The latest institutional shareholding proportion is 98.37%, representing a quarter-over-quarter decrease of 0.19%. The largest institutional shareholder is The Vanguard, holding a total of 23.86M shares, representing 9.31% of shares outstanding, with 3.28% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

28.73M

+0.70%

The Vanguard Group, Inc.

Star Investors

23.86M

+2.05%

Capital Research Global Investors

16.11M

+10.81%

BlackRock Institutional Trust Company, N.A.

14.15M

+1.12%

State Street Investment Management (US)

11.78M

-0.11%

Fidelity Management & Research Company LLC

6.30M

-17.28%

Jennison Associates LLC

6.15M

+21.51%

Geode Capital Management, L.L.C.

5.93M

+2.90%

Invesco Capital Management (QQQ Trust)

5.26M

-0.35%

Wellington Management Company, LLP

4.81M

-11.76%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 6.43, which is higher than the Pharmaceuticals industry's average of 5.13. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.